Table 3 Differences in claudin-18 marker level between the studied prostatic carcinoma cases regarding clinic-pathological data
Variable | Marker | |||||
|---|---|---|---|---|---|---|
CLDN18 expression (N = 100) | Chi square test | P value | ||||
Negative (N = 70) N% | Weak (N = 6) N% | Moderate (N = 8) N% | Strong (N = 16) N% | |||
Age groups (years) | ||||||
 ≤ 65 (64) | 42 65.6% | 6 9.4% | 6 9.4% | 10 15.6% | 1.778 | 0.715 |
 > 65 (36) | 28 77.8% | 0 0.0% | 2 5.6% | 6 16.7% | ||
pT | ||||||
T2 (56) | 34 60.7% | 2 3.6% | 8 14.3% | 12 21.4% | 5.382 | 0.118 |
T3 (44) | 36 81.8% | 4 9.1% | 0 0.0% | 4 9.1% | ||
LN | ||||||
Positive (42) | 12 28.6% | 6 14.3% | 8 19.0% | 16 38.1% | 29.59 | 0.000(HS) |
Negative (58) | 58 100.0% | 0 0.0% | 0 0.0% | 0 0.0% | ||
Stage | ||||||
I (12) | 12 100% | 0 0.0% | 0 0.0% | 0 0.0% | 13.83 | 0.03 (S) |
II (24) | 14 58.3% | 4 16.7% | 6 25.0% | 0 0.0% | ||
III (48) | 36 75.0% | 2 4.2% | 2 4.2% | 8 16.7% | ||
IV (16) | 8 50.0% | 0 0.0% | 0 0.0% | 8 50.0% | ||
Gleason grade group | ||||||
1 (10) | 0 0.0% | 2 20.0% | 4 40.0% | 4 40.0% | 21.12 | 0.000(HS) |
2 (4) | 0 0.0% | 2 50.0% | 0 0.0% | 2 50.0% | ||
3 (10) | 0 0.0% | 2 20.0% | 2 20.0% | 6 60.0% | ||
4 (38) | 32 84.2% | 0 0% | 2 5.3% | 4 10.5% | ||
5 (38) | 38 100% | 0 0.0% | 0 0.0% | 0 0% | ||
PSA level | ||||||
 < 4ng/ml (6) | 6 100% | 0 0.0% | 0 0.0% | 0 0.0% | 4.425 | 0.651 |
4–10ng/ml (56) | 34 60.7% | 4 7.1% | 8 14.3% | 10 17.9% | ||
 > 10ng/ml (38) | 30 78.9% | 2 5.3% | 0 0.0% | 6 15.8% | ||
Capsular invasion | ||||||
Present (36) | 28 77.8% | 2 5.6% | 2 5.6% | 4 11.1% | .967 | 0.898 |
Absent (64) | 42 65.6% | 4 6.2% | 6 9.4% | 12 18.8% | ||
LVI | ||||||
Present (34) | 28 82.4% | 2 5.9% | 2 5.9% | 2 5.9% | 2.340 | 0.529 |
Absent (66) | 42 63.6% | 4 6.1% | 6 9.1% | 14 21.2% | ||
Perineural invasion | ||||||
Present (52) | 38 73.1% | 2 3.8% | 6 11.5% | 6 11.5% | 2.036 | 0.609 |
Absent (48) | 32 66.7% | 4 8.3% | 2 4.2% | 10 20.8% | ||